These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 22011448

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
    Estes JM, Leath CA, Straughn JM, Rocconi RP, Kirby TO, Huh WK, Barnes MN.
    J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
    [Abstract] [Full Text] [Related]

  • 3. Aurora kinases as prognostic biomarkers in ovarian carcinoma.
    Mendiola M, Barriuso J, Mariño-Enríquez A, Redondo A, Domínguez-Cáceres A, Hernández-Cortés G, Pérez-Fernández E, Sánchez-Navarro I, Vara JA, Suárez A, Espinosa E, González-Barón M, Palacios J, Hardisson D.
    Hum Pathol; 2009 May; 40(5):631-8. PubMed ID: 19157502
    [Abstract] [Full Text] [Related]

  • 4. FEZ1/LZTS1 protein expression in ovarian cancer.
    Califano D, Pignata S, Pisano C, Greggi S, Laurelli G, Losito NS, Ottaiano A, Gallipoli A, Pasquinelli R, De Simone V, Cirombella R, Fusco A, Chiappetta G.
    J Cell Physiol; 2010 Feb; 222(2):382-6. PubMed ID: 19885841
    [Abstract] [Full Text] [Related]

  • 5. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
    Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J.
    Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
    [Abstract] [Full Text] [Related]

  • 6. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S, EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm.
    J Natl Cancer Inst; 2003 Jan 15; 95(2):113-25. PubMed ID: 12529344
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML.
    Clin Cancer Res; 1997 Jun 15; 3(6):999-1007. PubMed ID: 9815777
    [Abstract] [Full Text] [Related]

  • 8. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Jun 15; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy.
    Lassmann S, Shen Y, Jütting U, Wiehle P, Walch A, Gitsch G, Hasenburg A, Werner M.
    Clin Cancer Res; 2007 Jul 15; 13(14):4083-91. PubMed ID: 17634533
    [Abstract] [Full Text] [Related]

  • 10. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
    Lassus H, Staff S, Leminen A, Isola J, Butzow R.
    Gynecol Oncol; 2011 Jan 15; 120(1):11-7. PubMed ID: 20937525
    [Abstract] [Full Text] [Related]

  • 11. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP.
    Clin Cancer Res; 2000 Aug 15; 6(8):3260-70. PubMed ID: 10955812
    [Abstract] [Full Text] [Related]

  • 12. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B.
    Gynecol Oncol; 2013 May 15; 129(2):358-63. PubMed ID: 23438671
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 14. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH, An HJ.
    Int J Gynecol Pathol; 2011 May 15; 30(3):205-17. PubMed ID: 21464733
    [Abstract] [Full Text] [Related]

  • 15. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD, Zhang Q, Zhang Y.
    Ai Zheng; 2005 Aug 15; 24(8):1002-5. PubMed ID: 16086882
    [Abstract] [Full Text] [Related]

  • 16. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
    Gadducci A, Cianci C, Cosio S, Carnino F, Fanucchi A, Buttitta F, Conte PF, Genazzani AR.
    Anticancer Res; 2000 Aug 15; 20(6C):4793-9. PubMed ID: 11205220
    [Abstract] [Full Text] [Related]

  • 17. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM, Moore KN, Myers TK, Lanneau GS, McMeekin DS, Walker JL, Gold MA.
    Gynecol Oncol; 2009 Feb 15; 112(2):337-41. PubMed ID: 19041126
    [Abstract] [Full Text] [Related]

  • 18. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K, Bond VK, Im DD, Rosenshein NB.
    Am J Clin Oncol; 2010 Aug 15; 33(4):358-63. PubMed ID: 19875949
    [Abstract] [Full Text] [Related]

  • 19. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.
    Classe JM, Jaffre I, Frenel JS, Bordes V, Dejode M, Dravet F, Ferron G, Marchal F, Rigaud DB, Loussouarn D, Campion L.
    Eur J Surg Oncol; 2011 Nov 15; 37(11):971-7. PubMed ID: 21944959
    [Abstract] [Full Text] [Related]

  • 20. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.
    Gynecol Oncol; 2006 Dec 15; 103(3):831-40. PubMed ID: 16919315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.